- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501/revakinagene taroretcel-lwey
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 234 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 23
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 19 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- NT-501, Sham Procedure
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2022
- U.S. locations
- 16
- States / cities
- La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
- Conditions
- Macular Telangiectasia Type 2 (MacTel)
- Interventions
- L-serine, Placebo
- Drug · Other
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 4
- States / cities
- La Jolla, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501 CNTF Implant
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 3
- States / cities
- Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501, Sham
- Combination Product · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 119 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 22
- States / cities
- Beverly Hills, California • Colorado Springs, Colorado • Atlanta, Georgia + 18 more
- Conditions
- Macular Telangiectasia
- Interventions
- 577-nm PASCAL laser
- Device
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Other
- Eligibility
- 21 Years to 79 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Idiopathic Juxtafoveal Telangiectasia
- Interventions
- NT-501 implant
- Biological
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Cleveland, Ohio
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- NT-501 CNTF implant
- Combination Product
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 7
- States / cities
- Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 4 more
- Conditions
- Idiopathic Juxtafoveal Telangiectasia
- Interventions
- zeaxanthin
- Drug
- Lead sponsor
- Paul S. Bernstein
- Other
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- Ciliary neurotrophic factor (CNTF), Sham procedure, NT-501 Implant, NT-501 Implant procedure
- Biological · Procedure · Device
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more
- Conditions
- Macular Telangiectasia Type 2
- Interventions
- Serine, Fenofibrate
- Dietary Supplement · Drug
- Lead sponsor
- The Lowy Medical Research Institute Limited
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 89 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 8
- States / cities
- Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more
- Conditions
- MacTel (Macular Telangiectasia) Type 2
- Interventions
- Ciliary neurotrophic factor (CNTF), Surgery
- Biological · Procedure
- Lead sponsor
- Neurotech Pharmaceuticals
- Industry
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Los Angeles, California • Miami, Florida • Atlanta, Georgia + 5 more